ArticleInternational journal of clinical oncology2025

Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification.

Junya Furukawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.